Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorinda Simms

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Pageof 3